Agency
Ozark Health, INC
Ozark Health, INC was paid $3.46M by Medicaid between Jan 2018 and Dec 2024, across 87 billing codes. Its largest line is 11042, Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm — 13% of everything it billed.
33Billing provider infoOZARK HEALTH, INC
CLINTON, AR 72031
CLINTON, AR 72031
33aNPI1992760342assigned 04/19/2006
33bProvider typeHome Health Agency
28Total paid$3.46M
24GClaims117,759
24DCodes billed87
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Home Health Agency providers in Arkansas
Rank by total paid#16 of 139
Median peer was paid$360K
This provider vs. median9.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,295 | $337K | |
| 2019 | 18,068 | $574K | |
| 2020 | 17,482 | $466K | |
| 2021 | 18,360 | $547K | |
| 2022 | 16,235 | $542K | |
| 2023 | 15,700 | $570K | |
| 2024incomplete | 16,619 | $425K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 13% | 3,061 | 1,008 | $460K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 13% | 6,495 | 1,523 | $460K |
| 70450 | Computed tomography, head or brain; without contrast material | 11% | 2,292 | 2,026 | $371K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.8% | 7,436 | 5,843 | $303K |
| 80053 | Comprehensive metabolic panel | 5.2% | 10,244 | 7,905 | $180K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 4.5% | 3,586 | 3,034 | $157K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.4% | 1,467 | 1,292 | $151K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.3% | 11,696 | 8,586 | $114K |
| 72125 | Computed tomography, cervical spine; without contrast material | 2.6% | 642 | 559 | $90K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 435 | 386 | $85K |
| 87428 | 1.9% | 927 | 818 | $66K | |
| 82553 | 1.9% | 1,936 | 1,672 | $64K |
75 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 1,957 | $60K |
| 99284 | Emergency room visit (serious) | 1.7% | 1,439 | $60K |
| 71045 | Radiologic examination, chest; single view | 1.6% | 2,863 | $55K |
| 84484 | 1.5% | 2,486 | $52K | |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 1,900 | $48K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 3,536 | $44K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.2% | 3,819 | $42K |
| 82550 | 1.2% | 2,324 | $42K | |
| 87400 | 1.2% | 6,262 | $41K | |
| 83880 | <1% | 568 | $35K | |
| 80305 | <1% | 1,463 | $34K | |
| 83605 | <1% | 1,218 | $30K | |
| 81001 | <1% | 5,195 | $27K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,916 | $23K |
| 85027 | <1% | 2,278 | $23K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 69 | $18K |
| 73564 | <1% | 311 | $17K | |
| 87040 | <1% | 882 | $17K | |
| 84703 | <1% | 1,333 | $15K | |
| 73030 | <1% | 397 | $15K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 900 | $13K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,531 | $13K |
| 83690 | <1% | 906 | $13K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,805 | $12K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,003 | $12K |
| 87186 | <1% | 1,707 | $12K | |
| 85007 | <1% | 2,276 | $12K | |
| 87077 | <1% | 1,319 | $11K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 434 | $9K |
| 83735 | <1% | 1,003 | $8K | |
| 99285 | Emergency room visit (most serious) | <1% | 679 | $8K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 149 | $8K |
| 85730 | <1% | 815 | $8K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 224 | $7K |
| 73630 | <1% | 260 | $7K | |
| 73110 | <1% | 269 | $7K | |
| 85610 | <1% | 1,393 | $7K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 357 | $7K |
| 73130 | <1% | 188 | $7K | |
| 87420 | <1% | 528 | $6K | |
| 80050 | General health panel | <1% | 140 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 981 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 152 | $6K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,045 | $6K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 471 | $5K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 93 | $4K |
| 97161 | <1% | 83 | $4K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 604 | $4K |
| 87070 | <1% | 327 | $4K | |
| 73610 | <1% | 188 | $4K | |
| 87140 | <1% | 425 | $4K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 46 | $4K |
| 71020 | <1% | 162 | $3K | |
| 80306 | <1% | 119 | $3K | |
| 71250 | <1% | 13 | $3K | |
| 80320 | <1% | 147 | $2K | |
| 80061 | Lipid panel | <1% | 287 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 87 | $2K |
| 82607 | <1% | 86 | $1K | |
| 82150 | <1% | 88 | $921.10 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 151 | $697.14 |
| 73562 | <1% | 14 | $655.18 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 16 | $508.98 |
| 85379 | <1% | 37 | $460.67 | |
| 83090 | <1% | 26 | $313.17 | |
| 82728 | <1% | 27 | $259.12 | |
| 80329 | <1% | 14 | $236.00 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 476 | $229.20 |
| 82565 | <1% | 15 | $189.93 | |
| 82746 | <1% | 12 | $97.81 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 18 | $95.59 |
| 83540 | <1% | 15 | $95.43 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 104 | $42.44 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 48 | $0.00 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 63 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEATON, DAVID (CEO)
| Provider | Location | Paid |
|---|---|---|
| Ozark Health, INC | Clinton, AR | $359K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.